SPARTA Biodiscovery
Generated by Meeveem AI
"Enabling precise chemical analysis of individual nanoparticles for next generation therapeutics"
London
•11 - 50 Employees
•Medical Devices
About SPARTA Biodiscovery
SPARTA Biodiscovery develops analytical technology for pharmaceutical and biotechnology companies working with nanoformulations. Their patented SPARTA platform combines optical trapping with Raman spectroscopy to chemically analyse individual nanoparticles in an automated, label free process, addressing a critical gap where traditional bulk analysis cannot ensure each particle functions correctly. The technology characterises single particles in drug delivery systems, viral vectors, and exosomes with simultaneous size and chemical composition data. This accelerates development and quality control of next generation therapeutics by revealing heterogeneity at the individual particle level that conventional methods miss.
15
Team Members
2022
Founded
Medical Devices
Sector
Hybrid
Work Environment
Our Vision
A future where every therapeutic nanoparticle is fully characterised and optimised to deliver safer, more effective treatments for patients with previously untreatable conditions.
Our Mission
At SPARTA Biodiscovery, our mission is to accelerate the development of safer, more effective nanomedicines by enabling precise chemical characterisation of individual therapeutic nanoparticles.